Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide and lenalidomide in multiple myeloma.

Amitabha Mazumder1, Sundar Jagannath

  • 1New York Medical College, St Vincent's Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA.

Best Practice & Research. Clinical Haematology
|September 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Leukemia & lymphoma·2026
Same author

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same author

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

Current medical research and opinion·2026
Same author

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Lancet (London, England)·2026
Same author

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.

American journal of hematology·2026
Same author

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Blood·2026

New immunomodulatory drugs, thalidomide and lenalidomide, offer improved treatment for multiple myeloma, a plasma-cell cancer. These agents, along with proteasome inhibitors, represent significant progress in managing this incurable disease.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is a plasma-cell cancer that is treatable but not curable.
  • Treatment progress for multiple myeloma has been limited for decades.
  • Recent advancements have introduced novel drug classes for managing the disease.

Purpose of the Study:

  • To review the impact of new drug classes on multiple myeloma treatment.
  • To highlight the efficacy of immunomodulatory drugs and proteasome inhibitors.
  • To discuss the potential of these novel agents in managing incurable multiple myeloma.

Main Methods:

  • Review of recent clinical data on immunomodulatory drugs (thalidomide, lenalidomide) and proteasome inhibitors (bortezomib).
  • Analysis of drug activity as single agents and in combination therapies.

Related Experiment Videos

  • Evaluation of their role in induction therapy and controlling residual disease.

    • Main Results:

    • Thalidomide and lenalidomide show significant activity in chemotherapy-refractory myeloma, both alone and with glucocorticoids.
    • Combination therapy with thalidomide or lenalidomide and dexamethasone demonstrates promising induction therapy results.
    • These novel drugs can be combined with chemotherapy to enhance anti-myeloma effects and manage residual disease.

    Conclusions:

    • Immunomodulatory drugs and proteasome inhibitors have transformed multiple myeloma management.
    • These agents offer a new era of optimism for patients with this incurable cancer.
    • The immunomodulatory functions are key to controlling residual disease and improving outcomes.